Citations

Abstract Large PDX collections provide broad representation of tumor genetics and are commonly used to evaluate the clinical potential of novel therapeutic strategies. In many solid malignancies, profound benefit in PDX preclinical studies has foreshadowed eventual FDA approval of clinically impactful therapeutics. With a lack of corresponding progress in glioblastoma (GBM), the value of PDX testing has been questioned. Mayo Clinic has developed 111 GBM PDXs from newly diagnosed (72 PDX) and recurrent (39 PDX) patients, and over the past 23 years, we have used this collection for extensive in vivo preclinical testing of 145 drugs in both orthotopic and heterotopic settings. As part of this work, the impact of standard of care therapy with temozolomide (TMZ) and bevacizumab was evaluated in orthotopic models using clinically relevant dosing regimens. For each animal study, the ratio of median survival for treated vs. control animals were used to define a ‘survival ratio’ as a normalized metric of benefit. TMZ efficacy was evaluated in 26 newly diagnosed GBM PDXs, with equal representation of MGMT methylated and unmethylated tumors. As expected, MGMT methylated PDXs were much more sensitive to TMZ as compared to unmethylated PDXs (median survival ratio 4.47 vs 1.48, respectively), and similar to clinical experience, 2 MGMT unmethylated PDXs were markedly sensitive to TMZ, while 1 MGMT methylated PDX was relatively resistant. In a more limited study, dose-dense vs. standard TMZ dosing was compared in 7 PDXs (4 MGMT methylated, 3 MGMT unmethylated). In a pooled analysis of all lines, both standard (HR=0.09; 95% CI: 0.06–0.14) and dose-dense TMZ therapy (HR=0.09; 95% CI: 0.06–0.14) were superior to vehicle controls (p<0.001). Similar to the clinical results in the Phase III randomized RTOG 0525 trial, survival with the dose-dense TMZ was no different than standard dosing (p=0.88, HR=0.98; 95% CI: 0.72-1.32). In an analysis of bevacizumab across 32 PDXs, mice were dosed once a week until moribund, and a minimum overall median survival benefit of 20% was used to define ‘responders’. Thirteen PDXs met this criterion, although the overall survival ratio among this subset was limited (range 1.21-1.65). Only 2 models had a 50% or greater survival benefit. Stratification by disease state (24 newly diagnosed vs 8 recurrent) showed equivalent performance (median survival benefit 1.13 for both). These results are consistent with the limited survival benefit observed with bevacizumab and the RTOG 0825 clinical trial. In summary, the results from these relatively inexpensive PDX studies demonstrate the potential of pre-clinical PDX trials to evaluate the extent of benefit and fraction of responsive PDXs to a novel therapeutic. If analyzed across an ‘adequate’ number of PDXs, these results potentially can be used to identify predictive biomarkers or to compare various treatment regimens prior to clinical testing. Citation Format: Danielle M Burgenske, Ann C Mladek, Katrina K Bakken, Zeng Hu, Brett L Carlson, Paul A Decker, Jeanette E Eckel-Passow, Jann N Sarkaria. The utility of pre-clinical trials in glioblastoma patient-derived xenografts (PDXs) models for informing clinical trial development of therapeutic strategies [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr A002.

Abstract INTRODUCTION Disparities in breast cancer (BC) screening are observed between Hispanic and non-Hispanic White women and stronger amongst Hispanic women with under- and uninsured statuses.1-2 Risk-based screening has been recommended by professional societies, including American Cancer Society, starting at age 30 and may be an important strategy for reducing disparities.3 The purpose of the study was to characterize whether women had been told their personal risk of BC and to identify differences in characteristics of patients informed of their personal risk. METHODS This is a cross-sectional analysis of data from a supplemental self-reported survey to an NIH-funded randomized trial conducted at a large Federally Qualified Health Center (FQHC) in Arizona (R01 MD09682-05). The survey was sent to a randomized 600 of the 1,356 participants. Between November 2022 and April 2023, 177 women completed the survey (response rate 29.5%). Participants were asked if a doctor or other healthcare provider had ever talked to them about their personal risk for BC. Differences between those who recalled being told their personal risk for BC and those who did not were assessed using Fisher exact test. RESULTS Overall, 66.3% were 50 years or older, 81.8% who speak primarily Spanish, and 64.8% of respondents had less than a high school education. Also, 22.4% reported a family history of BC, 27.4% have been previously recalled for additional imaging, 10.8% have had a history of prior breast biopsy, 59.9% stated having a regular provider, and 53.1% were found to have dense breast category C or D at screening visit. 40% did not report having a regular doctor although all participants received care at an FQHC. 30.5% of respondents stated that a healthcare professional had ever talked to them about their personal risk for BC. There was a trend toward women with a main doctor being more likely to recall being told their personal risk for BC as compared to those without a main doctor (38.5% vs 22.5%, p=0.06). CONCLUSIONS In this cohort of primarily Spanish-speaking Hispanic women who have had mammography screening and written report of their breast density, about a third of respondents recall being informed of their personal BC risk. These observations need to be confirmed in a larger population with greater response rate, but these results suggest that there is a cohort of patients who need different approaches for conveying risk. REFERENCES 1. Jadav, S., Rajan, S. S., Abughosh, S., & Sansgiry, S. S. (2015). The Role of Socioeconomic Status and Health Care Access in Breast Cancer Screening Compliance Among Hispanics. Journal of Public Health Management and Practice, 21(5), 467–476. https://www.jstor.org/stable/48517175 2. American Cancer Society. (2017). Breast cancer facts & figures 2017-2018. Atlanta, GA: American Cancer Society, Inc. 3. ACS Breast Cancer Screening Guidelines. (2022, January 14). https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.htm Citation Format: Jhenitza P. Raygoza Tapia, Sarah M. Jenkins, Jennifer L. Ridgeway, Aaron D. Norman, Crystal R. Gonzalez, Valentina Hernandez, Bhavika K. Patel, Celine M. Vachon, Jessica D. Austin. Communicating breast cancer risk to Spanish-speaking Hispanic women [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr C126.

Abstract Introduction: The Patient Engagement-Cancer Genome Sequencing Research Center (PE-CGS; NCI U2C CA252973) based at the University of New Mexico Comprehensive Cancer Center (UNMCCC) with partners at Mayo Clinic Comprehensive Cancer Center, the Translational Genomics Research Institute, and the Black Hills for American Indian Health Research Center are developing culturally appropriate strategies and methods to address the underrepresentation of American Indians (AIs) in genomic research. Our efforts are directed towards the implementation of tailored cancer prevention, diagnosis, and treatment strategies that reduce cancer health disparities in Tribal communities. Methods: The PE-CGS Center has three units, each tasked with specific research components to engage AI participants in participatory, clinically-meaningful genomic research: 1) the Participant Engagement Unit; 2) the Genomics Characterization Unit; and 3) the Engagement Optimization Unit (EOU). The Center also has a Tribal Advisory Committee, composed of Tribal Governors, Presidents, and tribal health advocates and experts, who provide direction on all research matters. The PE-CGS EOU uses iterative rapid-cycle research techniques to optimize engagement and shares these strategies with other units for timely implementation. To date, the EOU has developed and implemented three key efforts. First, to aid in recruiting participants for the study, the EOU tailored a series (6) of participant-facing informational materials that include artwork from a local AI artist who combined her traditional and scientific knowledge to prepare complementary imagery. Second, the EOU is currently implementing a series of semi-structured discussions to document participant perceptions on criteria including engagement, communication, and education. Lastly, the EOU implemented a survey among UNMCCC providers on their return of results processes. Results: EOU discussions are ongoing and have provided important perspectives on participant satisfaction and areas for improvement. Participants have commended study staff on their efforts to make enrollment straightforward. Participants report discussing the study with family prior to enrolling, highlighting the importance of continuing to engage with the entire community on the goals of the study. The provider return of results survey is complete (n=42/62, response rate=68%); one key finding was that providers who return somatic test results rarely provide participants with a hard copy of the results or utilize complementary materials that might enhance their explanation of the test findings. Conclusion: The EOU serves an innovative function through its rapid-cycle methods to optimize participant engagement. Although participants are generally pleased with their study participation, there are numerous opportunities for improvement. The informational materials represent a novel contribution to the field of genomic research. Efforts will continue to implement optimized processes for effective engagement of AI communities in genomic research and cancer care delivery. Citation Format: Shoshana Adler Jaffe, Kendal Jacobson, Joseph Rodman, Cindy Blair, Debra MacKenzie, Mallery Quetawki, Tamar Ginossar, V. Shane Pankratz, Andrew Sussman, Ursa Brown-Glabermen, Jeffrey Trent, Cheryl Willman, Shiraz I. Mishra. The art of science: Painting a new image of genomic research in the indigenous communities of the Southwest [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr B134.

Abstract Background: Prostate cancer (PCa) in men is, to date, the number one cause of death from cancer worldwide. PCa has been associated with a large number of lifestyle factors, including unhealthy dietary habits. In particular, diet and nutrition have been shown to play pivotal roles in PCa, and the habitual consumption of certain specific foods like meat cooked at very high temperatures has been implicated. However, this has not been documented among Black men. The aim of this study was to determine the association between dietary patterns and their association with the occurrence of prostate cancer. Method: This is a longitudinal multisite Prostate Cancer Transatlantic Consortium (CaPTC) familial cohort phase 2 study. Participants were Nigerian Black men between 35 and 70 years old who were willing to participate in the study over a 10-year period. For the food variety score, a score of 1 was given for each food item eaten weekly, and the aggregate food variety score was totaled and categorized as ≥54% very good, 45%–53% was good, 36%–44% fair, 18%–35% poor and <18% was very poor. Data were analyzed using descriptive statistics, such as frequency analyses. Chi-square analysis was used to evaluate dichotomous variables to compare groups based on demographic factors and the occurrence of PCa. Multivariate logistic regression was used to determine the specific predictors of the diagnosis of PCa with potential adjustment for the other demographic variables. P-values < 0.05 was set as significant. Results: A total of 780 participants were recruited, with 72.6% reporting no history of cancer. The median age was 47.00 (range: 21-97),16.5% have been diagnosed with Pca, and 1.5% were diagnosed with other Cancers. Age of cancer diagnosis showed that 21% were diagnosed at about 50 years. Participants’ fruit consumption showed that 28.4%, 29%, 39.5%, 23%, 31%, 28.7%, and 39.2, ate apples, mango, citrus, papaya, green banana, tomatoes, and watermelon, weekly, respectively. Fish was the most consumed protein source of animal origin irrespective of the cooking methods categories, such as boiling, frying, grilling, and smoking. The median food variety score was 20 (0-67), with 8.5%, 3.8%,49.3%, and 26.8% classified as good, very good, poor, and very poor, respectively. Multivariate analysis showed that the category of food variety score (P=0.0009), age (P<0.0001), and grilled fish consumption (P=0.0333) were found to be associated with Pca occurrence. Conclusions: The study showed that food variety score, age, and fish consumption were the correlates of prostate cancer occurrence in the population studied. Citation Format: Opeyemi O. Bolajoko, Catherine A. Oladoyinbo, Daniel Lee, Oluwaseyi Toye, Parisa Fathi, Robert Turesky, Ademola Popoola, Iya Bassey, Solomon Rotimi, Paul Jibrin, Chidebere Ogo, Abidemi Omonisi, Adebanji Adeniji, Anthonia Showunmi, Omolara Fatiregun, Ayo Salako, Haruna Nggada, Faruk Mohammed, Ifeoma Okoye, Ernie Kaninjing, Folakemi Odedina. Association between dietary patterns and occurrence of prostate cancer among Nigerian men: The CaPTC Familial Cohort Study [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr B055.

Abstract Introduction: Black males face a higher incidence of prostate cancer compared to other racial and ethnic groups. Cardiovascular disorders, including hypertension and metabolic syndrome, are more frequently observed in black men with prostate cancer, significantly impacting their quality of life, treatment outcomes, and related challenges. Socioeconomic disparities and stress also pose significant challenges for black men who engage in substance use, such as tobacco or alcohol. The purpose of this study was to explore the prevalence of cardiovascular issues and substance abuse specifically among black males diagnosed with prostate cancer. Methods: This descriptive, cross-sectional study examined associations between substance abuse, cardiovascular co-morbidities, and diagnoses of prostate cancer in men in Nigeria, Africa. It utilized data collected from the Prostate Cancer Transatlantic Consortium (CaPTC) Familial Cohort Study, an ongoing longitudinal cohort study initiated in 2018 which explores risk factors of prostate cancer among African Black men in Nigeria, Cameroon, and the United States (U.S.). Descriptive statistics generated association tables for variables captured. Results: From 708 participants who resided in Nigeria, 117 reported prostate cancer diagnoses compared to 580 who denied any cancer diagnoses. Median age of participants was 50, most were married (98.1%), Christian (65.8%), college educated (29.4%), with professional occupations (29.4%) and an average household income of 1,000,000 + Naira (24.2%). Marijuana use and alcohol consumption were identified to have statistically significant associations with prostate cancer diagnoses (p=0.003, p<0.001, respectively), while smoking (p=0.13), weight (p=0.22), and annual physicals (p=0.39) were not found to be significant predictors of prostate cancer diagnoses. Conclusion: Both marijuana and alcohol use were found to have significant associations with prostate cancer diagnoses in Nigerian men. Further research is directed to explore similar associations in Black men of other locations to confirm. This study provides a glimpse of associations of substance use and cardiovascular concerns in black males with prostate cancer. It is crucial for interventions to identify and understand the role of substance dependence and cardiovascular disorders in black males with prostate cancer to effectively address all risk factors, implementing lifestyle modifications, and providing culturally appropriate care, ultimately improving outcomes and reducing health disparities. Citation Format: Brittany M. Norris, Marvin Fullwood, Daniel Lee, Folakemi Odedina. A descriptive study of substance use and cardiovascular issues among Nigerian men with prostate cancer [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr B123.

Abstract While the Joint Commission requires health care organizations (HCOs) to have plans for addressing health disparities effective in July, 2023, many HCOs were frustrated by their inability to consistently and accurately capture and apply social determinants of health (SDH) data to clinical care and research in the health ecosystem. Dr. Young Juhn, Director of the Mayo Clinic Precision Population Science Lab (PPSL) and his team, developed and applied a standardized individual-level SDH measure derived from publically available individual housing features known as HOUSES Index. This validated individual-level SDH measure is now available across all 50 states through the HOUSES Cloud Platform that is patient-contact free, automated, and HIPAA compliant. The Houses Index can be made available in real time through electronic health records (EHR’s) enabling clinicians and their patients to make a shared decision for treatment options with SDH taken under consideration. In addition, HOUSES Index is a valuable research tool for risk stratification for cancer outcomes, improving (and auditing) artificial intelligence (AI) model performance, assessing longitudinal change of SDH and geospatial patterns of outcomes, and monitoring proper representation of underserved populations in cancer research. In this presentation, Dr. Young Juhn will discuss the current challenges for capturing SDH data in health care, the HOUSES Index and Platform as the solutions and its implications on cancer care and research. Citation Format: Young Juhn. The HOUSES Platform for precision cancer care and research: A cloud-based nationwide measure for next generation patient-level social determinants of health [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr IA043.

Abstract The CaPTC prostate cancer (CaP) Familial Cohort study (CaPFCS) was launched in 2017 to explore the CaP risk factors of African Black men (ABM). The study design is a prospective study that observes and follows healthy ABM and ABM diagnosed with CaP. Aim: The specific aim is to provide recommendations on statistical considerations for cohort studies focused on cancer disparities, based on lessons learned from the CaPTC CaPFCS. Methodology: Study participants were ABM in Cameroon, Nigeria, and the US. Using validated measures, data were collected mostly by self-administered or research assistant administered survey using paper survey (especially in Cameroon and Nigeria) with the responses transferred to REDCap by research coordinators. The statistical analysis for the CaPTC CaPFCS focused on the baseline epidemiological, behavioral, clinical and anthropometric measures of Black men. A total of 819 participants were included in the analyses. Statistical analyses included descriptive statistics (sample median, range, frequency and percentages) and unadjusted logistic regression models. Results: Data collection for the CaPTC CaPFCS were by multiple investigators/research coordinators at multiple sites in Cameroon, Nigeria, and the US. In preparation for the data analyses, we noted data entry errors and/or misinterpretation of data entry, which required extensive cleaning of the database prior to the analyses. The biostatisticians spent significant effort cleaning and ensuring data validity prior to the analyses. Confounding variables is another statistical consideration for cohort studies, such as the CaPTC CaPFCS. There was variability observed across age, education levels, employment status, household income and CaP diagnosis based on country of residence. CaP diagnosis was not reported by any of the ABM in the US, which may be due to the fact that they were all recruited within the community and no recruitment took place in the clinic. Finally, the CaPTC CaPFCS has several variables. Performing a lot of statistical tests may result in false-positive findings at P<0.05.Conclusion: The advantage of the CaPFCS is that it allows the CaPTC investigators to study epidemiological, behavioral, clinical and anthropometric variables associated with CaP over time. Being a longitudinal cohort study, investigators can track the changes in exposure and outcomes over time.However, statistical considerations need to be at the fore-front of multi-center, transatlantic cancer disparity studies such as the CaPTC CaPFCS, from data collection to data entry. The use of web-based survey with the ability to enter data directly into REDCaP will significantly reduce (if not totally eliminate) the need for database cleaning. There are multiple strategies that can be used to reduce confounder effect, including statistical adjustment and multivariate analysis to adjust for the confounders. The use of propensity score methods have especially been found to be effective in controlling baseline confounding factors. Citation Format: Daniel Lee, CaPTC Investigators, Jennifer Crook, Ruth Enuka, Fathi Parisa, Emeka Iweala Iweala, Oluwole Kukoyi, Ernest Kaninjing, Oluwaseyi Toye, Paul Jibrin, Folakemi Odedina. Importance of statistical considerations in multi-center, transatlantic cancer disparity studies: Lessons learned from the CaPTC prostate cancer familial cohort study [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr C013.

Abstract There is a large and increasing rate of incarcerated individuals that face a risk of cancer. Cancer is the leading cause of death among the incarcerated population, resulting in a significantly shortened survival rate amongst said population. Very few studies have been conducted to truly assess the knowledge gap between incarceration and cancer outcomes. But, from the few that have been done, like the population-based study done by UF Radiation Oncology assistant professor, Dr. Oladeru, it was discovered that a higher risk of cancer mortality was prevalent in those who were diagnosed with cancer during their time incarcerated as well as one year post release than the general population. My goal and intent with this literature review is to open the conversation about possible ways to bridge the knowledge gap between cancer health disparities amongst incarcerated patients and contribution factors. Citation Format: Tamia Isaacs, Oluwadamilola Oladeru, Jian Li, Yoshiko Iwai. Bridging the gap: A literature review of cancer mortality and incarcerated individuals [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr C015.

Abstract Introduction: The relentless surge of prostate cancer rates is rapidly alarming public health officials, leaving a trail of shattered hopes among Black men in the United States. This toll reduces mortality for this population, the urgent need for effective solutions becomes more apparent. Survivorship care plans (SCPs) emerge as a beacon of hope, holding the potential to transform the provision of care. Within this tool lies the encapsulation of vital cancer-related information, passed from the oncology team to the resilient survivor and their primary care physician. However, despite the unwavering support of national governing bodies, a disheartening reality persists for Black male survivors, who never access these life-saving plans. The study purpose was to identify receipt of SCPs and the preferred communication delivery of health information among Black prostate cancer survivors. Methods: Utilizing a grounded theory approach, our study delved into the experiences of a convenience sample of seven Black male prostate cancer survivors. In-person and telephone-based semi-structured interviews we sought to unravel unique narratives. The research inquiries used open-ended questions (1) knowledge, awareness, and understanding of SCPs; (2) interactions with medical professionals; and (3) preferred methods of communication of healthcare information. Employing a line-by-line descriptive force coding method, we extracted pertinent statements by open and axial coding to generate specific codes to encapsulate information collected from an underserved population. Results: Thorough analysis revealed several distinct themes pertaining to survivorship care plans and preferred communication styles. The relevant findings were a lack of SCPs knowledge, an absence of post-treatment care, the profound influence of faith and family support, and the value of group settings. Despite receiving education on treatment, survivors expressed a sense of being left adrift, as if their medical professional team had failed to provide them with a clear roadmap for their survivorship journey. In the absence of proper guidance, survivors resorted to considering pre-treatment risk assessments as a makeshift substitute for a comprehensive survivorship care plan. Conclusion: The impact of our study’s findings resonates deeply, revealing a startling reality: Black male survivors in our sample possessed a distressing lack of knowledge about the post-treatment phase of survivorship. Instead, they relied on the support of their spouses or fellow survivors with whom they connected during treatment sessions. The removal of government mandates aimed at promoting SCPs likely contributes toward a disheartening knowledge disparities among many Black men, leaving them without clear guidance regarding the crucial phase of aftercare. Armed with this data, we have the opportunity to drive change and enhance the development of culturally tailored, interactive care plans specifically designed to support Black male survivors after they conquer prostate cancer treatment. Citation Format: Dottington Fullwood, Charles Waldon, Carol Thomas, Mary Ellen Young, Shannon Pressey, Folakemi T. Odedina, Brandon Snipe, Isela Villasenor. Unsilenced strength: Survivorship perspectives from Black prostate cancer survivors [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr B013.

Abstract Background: The Mayo Clinic Comprehensive Cancer Center (MCCCC) is uniquely positioned to address cancer health disparities globally through the Community Outreach & Engagement (COE) Office and Program’s resources and partnerships in the areas of cancer research, education, and training. The goal of the COE Global Oncology Initiatives (GOI) is to lessen the cancer burden on patients globally by building global capacity through research, education, and training in MCCC impact regions. While MCCCC continues to build institutional relationships worldwide through the GOI, it has specifically increased research collaborations in Africa over the past 5 years. The purpose of this study is to synthesize and report the global oncology reach through scholarly output of collaborative efforts in ongoing research activities with partnering African countries. By analyzing and documenting research outputs within this area, we aim to better understand research priorities and needs, increase inclusivity of African populations, and improve potential avenues for impactful studies in global alliance networks. Methods: Publications were found by using key search terms and by using the map feature on Mayo Clinic’s Elsevier-hosted publication database to locate partner institutions throughout Africa. Only publications in the past 5 years, which included an African researcher as an author, and are relevant to cancer research were included. Duplicate publications were removed from the final dataset. Results: There are 86 unique MCCCC members collaborating with 11 different African countries (Algeria, Egypt, Ghana, Kenya, Morocco, Nigeria, South Africa, Tanzania, Tunisia, Uganda, and Zimbabwe). A total of 50 unique publications have been published, with an African country being represented 72 times. The majority of MCCCC global oncology work is with researchers in Sub-Saharan nations (n=43). Egypt, however, has the largest single country representation (n=22), followed by South Africa (n=14) and Nigeria (n=13). 164 unique African researchers across 133 different institutions have worked with MCCCC members. Prostate and liver cancer were the most represented cancers at 6 instances, respectively. Discussion: Overall, 86 MCCCC members are involved in global research that address cancer health disparities through equal partnership with African researchers, which has resulted in multiple research output. Some of the publications were led by global consortia or cohort studies. These collaborations have been mutually beneficial for MCCCC members and African investigators, elevating cancer research in Africa. This includes increased research scholarship, extramural funding for cancer research in Africa, opening of more clinical trials across the continent, and increase in cancer biomedical workforce. Global research, especially one that is inclusive of the African populations, will foster the understanding of the genetic architecture of cancer, and help shape cancer care and control for Africans and people of African ancestry. Citation Format: Parisa Fathi, Manisha Salinas, Monica Albertie, Folakemi Odedina. Addressing cancer health disparities through global oncology initiatives at a comprehensive cancer center [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr A135.